Trial Profile
A multi-center, double-blind, parallel-group, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of denagliptin in subjects with type 2 diabetes mellitus
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Denagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 16 Apr 2015 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov
- 08 Nov 2006 Status change
- 28 Oct 2006 New trial record.